师资队伍


扫描此二维码分享

当前位置: 首页 > 师资队伍 > 正文

汪海涛

发布时间:2020年01月21日 浏览次数:



姓名:汪海涛

职称:副教授,硕士研究生导师

联系邮箱:wht821@smu.edu.cn

联系电话:020-61648594


学习经历:

2009.9-2012.12 中山大学,药理学,博士

2005.9-2008.6 南方医科大学,药理学,硕士

2000.9-2005.6 安徽中医学院,中医临床医学,学士


工作经历:

2019.06- 南方医科大学药学院,药理学, 副教授

2016.11-2019.06 南方医科大学药学院, 药理学, 讲师

2015.5-2016.6  多伦多大学医学院,神经生物学,博士后

2013.5-2016.10  南方医科大学,药学,博士后


研究方向:

神经精神疾病发病机制及药物筛选


主要学术任职:

1. 国际氧化还原生物学与医学学会(the Society for Redox Biology and Medicine, SfRBM),会员

2. 美国化学会(American Chemical Society, ACS),会员

3. 中国药理学会抗衰老与老年痴呆专业委员会青年委员会,常务委员

4. 中国药理学会神经精神药理专业委员会青年委员会,委员

5. 中国药理学会麻醉药理专业委员会青年委员会,委员

6. 获邀担任Br J PharmacolJ Med ChemBrain Behav ImmunJ NeurochemCell Mol Life SciCell Biol ToxicolCell SignalBiochem Pharmacol Acta Pharmacol Sin CNS Neurosci Ther Food Chem Toxicol Mol Neurobiol ACS Chem Neurosci Front Pharmacol Phytomedicine J PsychopharmacolBrain Res BullNeural Regen ResNeuropeptidesEur J Pharmacol 50余个SCI杂志审稿人。


在研科研课题:

1. 国家自然科学基金面上项目,PDE4在脑缺血再灌注过程中通过FoxO3a介导的铁自噬促进神经元铁死亡的作用及机制研究82173802, 2022.01-2025.1255万元,主持。

2. 广东省自然科学基金面上项目,PDE4调控帕金森病多巴胺能神经元线粒体自噬的机制及亚型选择性研究,2021A1515011133, 2021.01-2023.1210万元,主持。

3. 广州市科技计划项目,磷酸二酯酶4在脑缺血损伤中对神经元内质网应激的调控及机制研究,202002030494, 2020.04- 2023.0320万元,主持。


近三年代表性论文(2019-2021,通讯作者)

1. Dong WL, Zhong JH, Chen YQ, Xie JF, Qin YY, Xu JP, Cai NB, Li MF, Liu L, Wang HT. Roflupram protects against rotenone-induced neurotoxicity and facilitates α-synuclein degradation in Parkinson’s disease models. Acta Pharmacol Sin. 2021; doi: 10.1038/s41401-021-00768-4.. (IF=6.150).

2. Xu B, Xu J, Cai N, Li M, Liu L, Qin Y, Li X, Wang H. Roflumilast prevents ischemic stroke-induced neuronal damage by restricting GSK3β-mediated oxidative stress and IRE1α/TRAF2/JNK pathway. Free Radic Biol Med. 2021;163:281-296. (IF=7.376).

3. Xie J, Bi B, Qin Y, Dong W, Zhong J, Li M, Cheng Y, Xu J, Wang H. Inhibition of phosphodiesterase-4 suppresses HMGB1/RAGE signaling pathway and NLRP3 inflammasome activation in mice exposed to chronic unpredictable mild stress. Brain Behav Immun. 2021; 92:67-77. (IF=7.217).

4. Zhong J, Dong W, Qin Y, Xie J, Xiao J, Xu J, Wang H. Roflupram exerts neuroprotection via activation of CREB/PGC-1α signaling in experimental models of Parkinson's disease. Br J Pharmacol. 2020;177(10):2333-2350. (IF=8.739).

5. Xu B, Qin Y, Li D, Cai N, Wu J, Jiang L, Jie L, Zhou Z, Xu J, Wang H. Inhibition of PDE4 protects neurons against oxygen-glucose deprivation-induced endoplasmic reticulum stress through activation of the Nrf-2/HO-1 pathway. Redox Biol. 2020; 28:101342. (IF=11.799).

6. Xiao J, Yao R, Xu B, Wen H, Zhong J, Li D, Zhou Z, Xu J, Wang H. Inhibition of PDE4 Attenuates TNF-α-Triggered Cell Death Through Suppressing NF-κB and JNK Activation in HT-22 Neuronal Cells. Cell Mol Neurobiol. 2020;40(3):421-435. (IF=5.041).

7. Zhong J, Xie J, Xiao J, Li D, Xu B, Wang X, Wen H, Zhou Z, Cheng Y, Xu J, Wang H. Inhibition of PDE4 by FCPR16 induces AMPK-dependent autophagy and confers neuroprotection in SH-SY5Y cells and neurons exposed to MPP+-induced oxidative insult. Free Radic Biol Med. 2019;135:87-101. (IF=7.376).

8. Xu B, Wang T, Xiao J, Dong W, Wen HZ, Wang X, Qin Y, Cai N, Zhou Z, Xu J, Wang H. FCPR03, a novel phosphodiesterase 4 inhibitor, alleviates cerebral ischemia/reperfusion injury through activation of the AKT/GSK3β/β-catenin signaling pathway. Biochem Pharmacol. 2019;163:234-249. (IF=5.858).

9. Yu H, Zhong J, Niu B, Zhong Q, Xiao J, Xie J, Lin M, Zhou Z, Xu J, Wang H. Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors and Prevents Dendritic Spine Loss in Mice Hippocampi. Int J Neuropsychopharmacol. 2019;22(2):143-156. (IF=5.176).


参编专著:

1.  Wang H, Lazarovici P, Zheng W. Forkhead Box Protein O. In: Encyclopedia of Signaling Molecules, (Choi S ed.), Springer, New York, 2018.

2. Wang H. Cellular Proteostasis in Aging. In: Encyclopedia of Gerontology and Population Aging, (Danan Gu and Matthew E. Dupre ed.), Springer, New York, 2019.



上一条:姚新刚

下一条:王继刚